CNBC June 21, 2024
Key Points
– Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year.
– The company released additional data from two late-stage trials showing that Zepbound helped resolve obstructive sleep apnea in almost half of patients.
– The results add to growing evidence of additional health benefits tied to a buzzy class of weight loss and diabetes treatments, which have skyrocketed in popularity in the U.S. over the past year.
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the...
Today's Sponsors
Today's Sponsor